touchMDT

Multidisciplinary management of chronic myeloid leukaemia in the later-line setting: A holistic approach

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Leukaemia, Haematological Malignancies, Haematology, Supportive Cancer Care Watch Time: 46 mins

touchMDT Multidisciplinary management of chronic myeloid leukaemia in the later-line setting: A holistic approach

Watch chronic myeloid leukaemia (CML) specialists within a multidisciplinary team, plus a CML patient advocate, discuss the later-line management of CML.

Overview & Learning Objectives

Patient with previously treated chronic myeloid leukaemia

Haematologist & Pharmacist

A haematologist and a pharmacist consider the later-line treatment options for chronic myeloid leukaemia, including BCR::ABL1 T315I mutation-positive disease, in a case-based discussion.

Expert Spotlight
Prof. Dr. med. Andreas Hochhaus
Jena University Hospital, Jena, Germany
Dr Bee Kim Tan
Taylor’s University, Selangor, Malaysia

Prof. Dr. Andreas Hochhaus and Dr Bee Kim Tan discuss third-line treatment options for an elderly patient with T315I mutation-positive chronic myeloid leukaemia and cardiovascular comorbidities.

Listen on the Go

Learn more Back to MDT Hub Time: 12:44
 
Nurse specialist & Haematologist

A nurse specialist and a haematologist consider how to best minimize toxicities while maximizing treatment benefit for patients with chronic myeloid leukaemia, in a case-based discussion.

Expert Spotlight
Mr Johan De Munter
University Hospital Ghent, Ghent, Belgium and European Oncology Nursing Society, Brussels, Belgium
Prof. Dr. med. Andreas Hochhaus
Jena University Hospital, Jena, Germany

Mr Johan De Munter and Prof. Dr. Andreas Hochhaus consider how to best minimize toxicities while maximizing treatment benefit in a patient with chronic myeloid leukaemia experiencing side effects with a second-line tyrosine kinase inhibitor.

Listen on the Go

Learn more Back to MDT Hub Time: 11:58
 
Pharmacist & Nurse specialist

A pharmacist and a nurse specialist consider strategies to help maximize quality of life for patients with chronic myeloid leukaemia in the later-line setting, in a case-based discussion.

Expert Spotlight
Dr Bee Kim Tan
Taylor’s University, Selangor, Malaysia
Mr Johan De Munter
University Hospital Ghent, Ghent, Belgium and European Oncology Nursing Society, Brussels, Belgium

Dr Bee Kim Tan and Mr Johan De Munter consider strategies to help maximize quality of life in a woman with chronic myeloid leukaemia on a second-line tyrosine kinase inhibitor who has psychological comorbidities and wishes to start a family.

Listen on the Go

Learn more Back to MDT Hub Time: 09:15
 
Haematologist, Patient advocate & Nurse specialist

A chronic myeloid leukaemia (CML) patient advocate speaks with a haematologist and a nurse specialist to provide real-life perspectives on how outcomes can be improved in patients with CML.

Expert Spotlight
Prof. Dr. med. Andreas Hochhaus
Jena University Hospital, Jena, Germany
Ms Jelena Čugurović
CML Association of Serbia, Belgrade, Serbia
Mr Johan De Munter
University Hospital Ghent, Ghent, Belgium and European Oncology Nursing Society, Brussels, Belgium

Ms Jelena Čugurović provides real-life patient perspectives on how outcomes can be improved in patients with chronic myeloid leukaemia, in discussion with Prof. Dr. Andreas Hochhaus and Mr Johan De Munter.

Listen on the Go

Learn more Back to MDT Hub Time: 12:50
 
Back To Top
Overview & Learning Objectives
Overview

In this activity, specialists in the multidisciplinary team involved in caring for patients with chronic myeloid leukaemia (CML), plus a patient advocate, share their perspectives on the later-line treatment of CML, including treatment options, managing tyrosine kinase inhibitor-associated toxicities and maximizing quality of life for patients with CML.

Learning Objectives

After watching this activity, participants should be better able to:

  • Discuss the later-line treatment of chronic myeloid leukaemia, including T315I mutation-positive disease
  • Manage the toxicities associated with tyrosine kinase inhibitor treatments for chronic myeloid leukaemia
  • Recognize the impact of tyrosine kinase inhibitors on quality of life for patients with chronic myeloid leukaemia
Faculty & Disclosures
Prof. Dr. med. Andreas Hochhaus

Jena University Hospital, Jena, Germany

Prof. Dr. med. Andreas Hochhaus is Head of the Department of Hematology and Medical Oncology and Coordinator of the University Tumor Center (UTC) at the Jena University Hospital, Jena, Germany. read more

He has been involved in treatment optimization of chronic myeloid leukaemia (CML) and the management of randomized CML studies of the German CML Study Group for more than 30 years. As co-chair of the German CML Alliance his focus is to enhance patient access to clinical trials. 

Prof. Dr. Hochhaus’ special interests are the molecular monitoring of minimal residual disease and mechanisms of resistance in CML. He is a member of the European Hematology Association and the American Society of Hematology. He served as president of the Annual Meeting of the German, Austrian, and Swiss Societies of Hematology and Oncology in 2016 and the German Cancer Congress in 2020. 

Prof. Dr. Hochhaus has published over 610 peer-reviewed papers and is regularly invited to speak at national and international symposia. He was awarded the Endowed Professorship for Leukaemia Research from the German José Carreras Leukaemia Foundation in 2007.

Prof. Dr. med. Andreas Hochhaus discloses: Institutional research support from BMS, Incyte, Novartis and Pfizer.

Mr Johan De Munter

University Hospital Ghent, Ghent, Belgium and European Oncology Nursing Society, Brussels, Belgium

Johan De Munter is a Nurse Manager at the University Hospital Ghent Cancer Center, Ghent, Belgium. read more

He has been a registered nurse in oncology-haematology for 21 years. 

During his early years as an oncology nurse, he obtained postgraduate degrees in pain management and in oncology. In 2010, he joined the University Hospital Ghent as a nurse consultant for the haematology/stem cell transplant unit. Mr De Munter has since expanded his expertise in healthcare provider and patient education, supportive care needs, adolescents and young adults with cancer, and transition and survivorship care. In 2016, he completed a postgraduate certificate in Teenage/Young Adult Cancer Care at Coventry University in the UK, and recently finished a postgraduate degree in leadership. He is a frequent guest teacher in various postgraduate courses for nurses and allied healthcare professionals.

Mr De Munter was a member and board member of the Flemish Society of Cancer Nurses, is a member of the Belgian Haematology Society nurses group and has been a member of the European Oncology Nursing Society since entering the profession. He is currently a board member in the Majinhuis, a community support home for people affected by cancer, and a member of the Belgian Federal Council of Nursing. After several roles in the European Oncology Nursing Society, he became the President of the organization in January 2021. 

He is committed to enhancing the field of nursing by building together and advocating for innovative care, education and research for the benefit of all cancer nurses, and by improving the quality of life for people with cancer.

Mr Johan De Munter has no financial interests/relationships or affiliations in relation to this activity.

Dr Bee Kim Tan

Taylor’s University, Selangor, Malaysia

Dr Bee Kim Tan is a Senior Lecturer at the School of Pharmacy, Faculty of Medicine and Health Sciences, Taylor’s University, Selangor, Malaysia. read more

Dr Tan was the Chief Pharmacist at Pantai Hospital Cheras, Kuala Lumpur, Malaysia before entering academia. 

She obtained her PhD in Medicine (Clinical Pharmacy) from the University of Malaya, Malaysia, her MSc in Clinical Pharmacy, Practice and Policy from the School of Pharmacy, University of London, UK, and her BPharm from the University of Malaya. She has taught both undergraduate (BPharm) and postgraduate (MPhil Pharmaceutical Sciences) programmes. 

Dr Tan’s research interests are in optimizing the use of tyrosine kinase inhibitors in chronic myeloid leukaemia, and its impact on patients’ treatment adherence, clinical outcomes and quality of life.

Dr Bee Kim Tan has no financial interests/relationships or affiliations in relation to this activity.

Ms Jelena Čugurović

CML Association of Serbia, Belgrade, Serbia

Jelena Čugurović is the Leader of the patient organization, CML Association of Serbia, and a Co-chair of the Central and Eastern Europe and West Asia region in the CML Advocates Network. read more

She has more than 10 years’ experience in advocacy, working closely with patients, caregivers, doctors and other stakeholders in Serbia and globally. 

Ms Čugurović’s specialty is the Central and Eastern Europe and West Asia regions, with all their diversity. Her work is devoted to helping people with chronic myeloid leukaemia (CML) around the world to gain access to the best therapies and to achieve optimal quality-of-life outcomes. 

Ms Čugurović believes that worldwide progress in the management of CML can only be made by working closely with all stakeholders in CML care.

Ms Jelena Čugurović discloses: Advisory board or panel fees from Novartis (relationship terminated). Grants/research support from Novartis (relationship terminated).

Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
Feedback Close
Feedback

Please provide feedback for this touchMDT on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
social_linkedin_altaccredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavataravatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubesponsored shape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12NEW TMM Corporate Services Icons-13Artboard ? NEW TMM Corporate Services Icons-15 Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72TMM-Corp-Site-Icons-73